← All trials
NCT05115136
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 8, 2021
- Primary completion
- Jan 31, 2023
- Completion date
- Jul 1, 2023
- First posted
- Nov 10, 2021
- Last posted
- Nov 10, 2021
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- State University of New York, SyracuseLead sponsor
- State University of New York, SyracuseReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.